Who are Vancomycin 1.1%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vancomycin oral liquid, Vancomycin / Linezolid, Vancomycin (or equivalent), Vancomycin capsules, Vancomycin CI, Teicoplanin antimicrobial-lock solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vancomycin-1-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Vancomycin 1.1% — Competitive Intelligence Brief

Vancomycin 1.1% (Vancomycin 1.1%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: glycopeptide antibiotic. Area: Infectious Disease.

phase 3 glycopeptide antibiotic D-alanyl-D-alanine terminus of cell wall precursors Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Vancomycin 1.1% (Vancomycin 1.1%) — Kurobe LLC. Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Vancomycin 1.1% TARGET	Vancomycin 1.1%	Kurobe LLC	phase 3	glycopeptide antibiotic	D-alanyl-D-alanine terminus of cell wall precursors
Vancomycin oral liquid	Vancomycin oral liquid	Astellas Pharma Europe B.V.	phase 3	glycopeptide antibiotic	D-alanyl-D-alanine terminus of cell wall precursors
Vancomycin / Linezolid	Vancomycin / Linezolid	Durata Therapeutics Inc., an affiliate of Allergan plc	phase 3	glycopeptide antibiotic / oxazolidinone	D-alanyl-D-alanine terminus of cell wall precursors / 50S ribosomal subunit
Vancomycin (or equivalent)	Vancomycin (or equivalent)	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	phase 3	glycopeptide antibiotic	D-alanyl-D-alanine terminus of cell wall precursors
Vancomycin capsules	Vancomycin capsules	Astellas Pharma Europe B.V.	phase 3	glycopeptide antibiotic	D-alanyl-D-alanine terminus of cell wall precursors
Vancomycin CI	Vancomycin CI	Wake Forest University Health Sciences	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor
Teicoplanin antimicrobial-lock solution	Teicoplanin antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Glycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (glycopeptide antibiotic class)

Astellas Pharma Europe B.V. · 2 drugs in this class
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
Kurobe LLC · 1 drug in this class
Major Extremity Trauma Research Consortium · 1 drug in this class
Savara Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vancomycin 1.1% — Competitive Intelligence Brief. https://druglandscape.com/ci/vancomycin-1-1. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab